These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 29306515)

  • 41. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.
    Huang SP; Huang LC; Ting WC; Chen LM; Chang TY; Lu TL; Lan YH; Liu CC; Yang WH; Lee HZ; Hsieh CJ; Bao BY
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3068-74. PubMed ID: 19900942
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prostate specific antigen only progression of prostate cancer.
    Moul JW
    J Urol; 2000 Jun; 163(6):1632-42. PubMed ID: 10799151
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Ultrasensitive prostate specific antigen after prostatectomy reliably identifies patients requiring postoperative radiotherapy.
    Kang JJ; Reiter RE; Steinberg ML; King CR
    J Urol; 2015 May; 193(5):1532-8. PubMed ID: 25463990
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence.
    Suardi N; Briganti A; Salonia A; Rigatti P
    Curr Opin Urol; 2011 May; 21(3):237-40. PubMed ID: 21427585
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Re: Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen.
    McDonald MW
    J Urol; 1998 Oct; 160(4):1442. PubMed ID: 9751386
    [No Abstract]   [Full Text] [Related]  

  • 46. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
    Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
    J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
    Narita S; Mitsuzuka K; Tsuchiya N; Koie T; Kawamura S; Ohyama C; Tochigi T; Yamaguchi T; Arai Y; Habuchi T;
    Int J Urol; 2015 Nov; 22(11):1029-35. PubMed ID: 26290306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base.
    Freedland SJ; Kane CJ; Presti JC; Terris MK; Amling CL; Dorey F; Aronson WJ
    J Urol; 2003 Mar; 169(3):969-73. PubMed ID: 12576824
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    J Urol; 2009 Nov; 182(5):2250-5. PubMed ID: 19758614
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Should we perform imaging-guided lymph node dissection in patients with lymphatic recurrence of prostate cancer after radical prostatectomy?
    Martorana G; Schiavina R; Franceschelli A
    Eur Urol; 2009 Jun; 55(6):1302-4. PubMed ID: 18707806
    [No Abstract]   [Full Text] [Related]  

  • 52. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
    Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
    Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy.
    Hofer C; Laubenbacher C; Block T; Breul J; Hartung R; Schwaiger M
    Eur Urol; 1999; 36(1):31-5. PubMed ID: 10364652
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patient evaluation if prostate-specific antigen becomes elevated following radical prostatectomy or radiation therapy.
    Ferguson JK; Oesterling JE
    Urol Clin North Am; 1994 Nov; 21(4):677-85. PubMed ID: 7526514
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy?
    de la Taille A; Rubin MA; Bagiella E; Olsson CA; Buttyan R; Burchardt T; Knight C; O'Toole KM; Katz AE
    J Urol; 1999 Jul; 162(1):103-6. PubMed ID: 10379750
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Salvage radiotherapy for prostate-specific antigen relapse after radical prostatectomy for prostate cancer: a single-center experience.
    Yoshida T; Nakayama M; Suzuki O; Matsuzaki K; Kobayashi Y; Takeda K; Arai Y; Kakimoto K; Nishiyama K; Nishimura K
    Jpn J Clin Oncol; 2011 Aug; 41(8):1031-6. PubMed ID: 21693484
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Significance of PSA nadir as a tool of predicting biochemical failure after radical prostatectomy for prostate cancer].
    Kinoshita H; Kawa G; Matsuda T; Ogawa O
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():395-8. PubMed ID: 22208009
    [No Abstract]   [Full Text] [Related]  

  • 59. Prostate MR Imaging for Posttreatment Evaluation and Recurrence.
    Gaur S; Turkbey B
    Urol Clin North Am; 2018 Aug; 45(3):467-479. PubMed ID: 30031466
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy.
    Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
    Urology; 2004 Dec; 64(6):1165-70. PubMed ID: 15596191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.